World Economic Forum Technology Pioneer in Stem Cell Research Invited to Speak at Israel Innovation Summit 2006

Share Article

Dr. Valentin Fulga, CEO of the TheraVitae Group, the producer of VesCell™ -- Adult Stem Cell Therapy for Heart Disease, has been invited to speak at the inaugural Israel Innovation Summit 2006. The Summit will be held on 4-5 April at the Haifa Congress Center, Haifa, Israel. The World Economic Forum recently named Dr. Fulga as one of its 2006 Technology Pioneers for his work in adult stem cell therapy.

Dr. Valentin Fulga, Co-Founder and CEO of TheraVitae, has been invited to speak at the inaugural Israel Innovation Summit 2006. This groundbreaking summit brings together leading researchers, entrepreneurs and venture capitalists from Israel and abroad; all committed to a common goal of striving to discover the breakthrough technologies and treatments of tomorrow.

The Summit is the first of its kind in Israel and will accelerate innovation through the sharing of knowledge, collaborations, and investments. World-class researchers from leading universities will explore their applied activities and unveil future technologies, making it an ideal networking platform. Commenting on his invitation to speak during the two day conference, Dr. Fulga stated, “It is an honor to have this opportunity to present our adult stem cell technology and its vast potential at this distinguished meeting. We are delighted that the organizers regard TheraVitae as a leading innovator and have chosen to include us amongst the select group of companies attending the Summit.”

Joining Dr. Fulga for the round table session on Cell and Gene Therapy, chaired by Dr. Nissim Darvish, a Partner in Pitango Venture Capital are:

  • Prof. Dror Harats, M.D., Head, Institute of Lipid & Atherosclerosis Research, Haim Seba Medical Center at Tel Hashomer and CEO, Vascular Biogenics,
  • Dr. Shulamit Levenberg, Biomedical Engineering Department, Technion
  • Prof. Raymond Kaempfer, CSO, Atox Bio Ltd. Faculty of Medicine, The Hebrew University of Jerusalem

On the heels of his recognition as one of the World Economic Forum’s Technology Pioneers for 2006, and in the wake of the growing success of VesCell, TheraVitae’s proprietary adult stem cell therapy for heart disease which has now been used to treat over 100 patients including famed Hawaiian entertainer Don Ho, Dr. Fulga remarked, “More and more patients are being successfully treated with our therapy every day. Consequently, our technology is gaining an increasing amount of recognition in the scientific and medical communities. This bolsters our confidence in developing additional therapies for other severe disorders, such as critical limb ischemia.

About The Israel Innovation Summit (IIS) 2006

On April 4-5, 2006 an inspiring international gathering of academia, start ups, entrepreneurs, emerging companies, NASDAQ stars and global corporations will meet for The Israel Innovation Summit, at the Haifa Congress Center, Israel.

The first conference of its kind in Israel, the Israel Innovation Summit offers a look into the future in Cell and Gene Therapy, Distributed Computing, Nano Electronics and more. The Summit will act as a meeting platform where breakthrough technology will be introduced and discussed by leading experts, corporate investors and venture capitalists from around the world.

World class keynote speakers -- from the US, Europe and Israel -- will make presentations, including CEOs and Senior Vice Presidents of multinational leading companies. Top researchers will present their visions for the new frontiers of technology which are ready for implementation. Panel discussions with Israeli public companies and global leading corporations will also take place.

IIS 2006 Website:

About VesCell™ -- A Natural Treatment for Heart Disease

The body has natural ways of healing itself and the cardiovascular system is no exception. Angiogenic Cell Precursors (ACPs) originate in bone marrow and then circulate in the blood vessels. To manufacture VesCell™, TheraVitae expands a small number of ACPs harvested from about 250cc of blood into a therapeutic quantity. VesCell™ is injected either through a coronary artery via catheter, or during minimally invasive surgery, directly into the heart muscle. VesCell™ uses a patient's own adult stem cells to treat Heart Disease and is a viable therapeutic possibility for heart patients without any other treatment option.

Additional Information on Stem Cell Therapy:

VesCell™ Website:
Stem Cell Therapy Blog:

About TheraVitae

TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, and Hong Kong.

TheraVitae Thailand

36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110

Phone: 02-664-4290/3

Fax: 02-664-42-89

TheraVitae Israel

7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel

Phone: +972-8-9409170

Fax: +972-8-9409167

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay D. Lenner Jr.
Email >
Visit website